DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Mizokami M, Yokosuka O, Takehara T. , et al.
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Lancet Infect Dis 2015;
15 (06) 645-653
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.